undamentalytics Newsletter
Sign in

Travere Therapeutics, Inc. income statement

In fiscal 2025, Travere Therapeutics, Inc. reported revenue of $491m, up 110.5% on the year before, operating income of −$62.8m (a -12.8% margin) and net income of −$25.5m, or −$0.29 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Feb 20112012Feb 20122016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue00134155164175198132109145233491651
Cost of revenue——54656441181010
Gross profit——129151159170192128105134225480641
Research and development——71781241411322018245217206246
Selling, general and administrative——92101104129136126198266264337418
General and administrative00———————————
Operating income——−58−54−80−137−176−199−320−388−324−63−133
Interest expense——5410191920111111119
Net interest income——435————————
Income before tax——−58−58−102−146−189−217−331−376−321−49−160
Income tax——−1011−0−1900001−5
Net income−0—−48−60−103−146−169−180−278−111−322−26−122
Diluted EPS——−$1.29−$1.54−$2.54−$3.46−$3.56−$3.01−$4.37−$1.50−$4.08−$0.29−$1.36
Diluted shares (average)——38m39m40m42m48m60m64m74m79m89m89m
EBITDA——−42−36−61−117−152−187−299−350−280−2−81

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EBS vs TVTXALVO vs TVTXAMPH vs TVTXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Travere Therapeutics, Inc.